Chugai Pharmaceutical Co., Ltd. (F:CUP0) — Market Cap & Net Worth
Market Cap & Net Worth: Chugai Pharmaceutical Co., Ltd. (CUP0)
Chugai Pharmaceutical Co., Ltd. (F:CUP0) has a market capitalization of $83.12 Billion (€71.09 Billion) as of April 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #305 globally and #30 in its home market, demonstrating a -5.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chugai Pharmaceutical Co., Ltd.'s stock price €21.60 by its total outstanding shares 3291426838 (3.29 Billion).
Chugai Pharmaceutical Co., Ltd. Market Cap History: 2026 to 2026
Chugai Pharmaceutical Co., Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $83.12 Billion to $83.12 Billion (0.00% CAGR).
Chugai Pharmaceutical Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chugai Pharmaceutical Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CUP0 by Market Capitalization
Companies near Chugai Pharmaceutical Co., Ltd. in the global market cap rankings as of April 18, 2026.
Key companies related to Chugai Pharmaceutical Co., Ltd. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $829.71 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $564.21 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #33 globally with a market cap of $368.45 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $317.50 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $829.71 Billion | $927.03 |
| #19 | Johnson & Johnson | NYSE:JNJ | $564.21 Billion | $234.18 |
| #33 | AbbVie Inc | NYSE:ABBV | $368.45 Billion | $208.38 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $317.50 Billion | $204.80 |
Chugai Pharmaceutical Co., Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Chugai Pharmaceutical Co., Ltd.'s market cap moved from $83.12 Billion to $ 83.12 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €83.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Chugai Pharmaceutical Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $83.12 Billion USD |
| MoneyControl | $83.12 Billion USD |
| MarketWatch | $83.12 Billion USD |
| marketcap.company | $83.12 Billion USD |
| Reuters | $83.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal … Read more